Amy Hurlburt, DO
Internal Medicine · Tulsa, OKNPI 1598921199
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $9,637 of the $12,240 with a category attached, or 78.7%. Astellas Pharma US Inc accounts for 82.9% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2023 at $6,574 and has fallen 96.6% since, to $226 in 2025. Among internal medicine clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 114 payments — averaging $107.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$10K
- Novo Nordisk$534
- AbbVie$456
- Abbott$312
- Lilly USA, LLC$283
- Amgen$98
- plus $416 from 17 others
What the payments were for
- Speaking & faculty fees$9,63779%
- Travel & lodging$3403%
- Food & beverage$2,13117%
- Education$1331%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 19 | $10,142 |
| Novo Nordisk | 25 | $534 |
| AbbVie(2 entities) | 22 | $456 |
| Abbott | 6 | $312 |
| Lilly USA, LLC | 15 | $283 |
| Amgen | 5 | $98 |
| Hologic Sales And Service, LLC | 2 | $74 |
| Boehringer Ingelheim | 3 | $49 |
| Sumitomo Pharma America, Inc. | 2 | $43 |
| Pfizer | 2 | $31 |
| Pharmacosmos Therapeutics Inc. | 1 | $23 |
| Mylan Pharmaceuticals Inc. | 1 | $23 |
| Bayer | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $20 |
| AMAG Pharmaceuticals, Inc. | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $19 |
| Agile Therapeutics, Inc. | 1 | $18 |
| AstraZeneca | 1 | $14 |
| CSL Behring | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
| Genentech USA, Inc. | 1 | $12 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $11 |
| Shire North American Group Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Veozah$9,472
- FREESTYLE LIBRE 3$131
- FreeStyle Libre 2$122
- Saxenda$115
- Wegovy$114
How this compares
$12,240 in reported general payments places this provider in the 95th percentile of 840 internal medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 61 | $83,428 |
| OzempicSemaglutide | 17 | $25,120 |
| FarxigaDapagliflozin Propanediol | 14 | $15,099 |
| EliquisApixaban | 13 | $10,032 |
| JanuviaSitagliptin Phosphate | 13 | $6,945 |
| Estradiol | 31 | $2,489 |
| Duloxetine Hcl | 28 | $888 |
| Atorvastatin Calcium | 71 | $801 |
| Aripiprazole | 19 | $782 |
| Rosuvastatin Calcium | 31 | $752 |
| Omeprazole | 28 | $597 |
| Doxycycline Monohydrate | 15 | $537 |
| Vitamin D2Ergocalciferol (Vitamin D2) | 30 | $525 |
| Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine | 12 | $500 |
| Clobetasol Propionate | 12 | $436 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $283 | $83,42861 claims |
| Novo NordiskOzempic | $534 | $25,12017 claims |
| AstraZenecaFarxiga | $14 | $15,09914 claims |
| PfizerEliquis | $31 | $10,03213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 840 internal medicine providers in Oklahoma.
Other internal medicine in Tulsa
- Jesse RichardsTulsa$279K
- Madhuri LadTulsa$173K
- Stacy ChronisterTulsa$163K
- Layth Al AttarTulsa$35K
- Gerard McNultyTulsa$27K
- Peter LantzTulsa$23K
- Sudip TripathyTulsa$21K
- John RuffingTulsa$21K
- Joseph ReeseTulsa$18K
- Mark GallesTulsa$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.